ATMP Sweden

Great listening to 'Beyond Tomorrow' with Ewa Ellis, ATMP coordinator at Karolinska Universitetssjukhuset and key figure in shaping ATMP 2030🎙️ Ewa shares invaluable insights into Sweden’s progress toward becoming a world leader in Advanced Therapies, discussing ATMP 2030, the key players, challenges, and opportunities shaping our field.

🌐 Collaboration: The Backbone to innovate in ATMP HOYA’s latest newsletter highlights Heather Main’s reflections working with the ATMP Sweden platform over the past 6.5 years, emphasizing the critical role of collaboration, stakeholder engagement, and ecosystem mapping in advancing swedish ATMP.

🔬✨ Strengthening Sweden's ATMP Ecosystem! ✨🔬 We’re excited to see member organizations like CCRM Nordic, in collaboration with NextGenNK, driving important initiatives like the ATMP Mini-Symposium on January 22, 2025, at Karolinska Institutet’s ATMP Flemingsberg Campus. This symposium will provide a valuable platform for exchanging insights and building connections within the Swedish ATMP community, highlighting the exciting academic and commercial developments in Stockholm and beyond. Hope to see you there! 💫

Advancing Cancer Immunotherapy: New CAR T-Cell Trial Underway 🔬 At Akademiska Hospital, a groundbreaking clinical trial is underway testing enhanced CAR T-cells, a cutting-edge therapy developed at Uppsala University. This innovation targets lymphoma patients who have relapsed or are unresponsive to current CAR T-cell treatments. What makes it special? These CAR20(NAP)-T cells target the CD20 protein and release a bacterial protein (NAP) to spark a broad immune attack on tumors. Early results are promising, with potential to expand treatment options to other cancers and even autoimmune diseases like MS and SLE. 🎯 The goal: To offer curative solutions for patients with limited options. 💡 This exciting step reflects the power of collaboration between Akademiska sjukhuset, Uppsala universitet, and Elicera Therapeutics AB , supported by the new ATMP Center Uppsala. Read more here: https://lnkd.in/gicG4Y5P

🎉 Exciting news from member NEOGAP Therapeutics AB! Neogap Therapeutics has achieved ATMP classification from the European Medicines Agency for their personalized cell therapy, pTTL (personalized Tumour Trained Lymphocytes), aimed at treating cancer. This milestone confirms that pTTL meets the stringent regulatory criteria for advanced therapies and provides a clear pathway for clinical trials and market approval. Currently being evaluated in a clinical phase I/II study for advanced colorectal cancer, pTTL holds the promise of innovative, patient-specific treatments for those with limited options. Congratulations to the Neogap team on this important step forward! 👏

Welcome Samplix to ATMP Sweden membership! Samplix Xdrop® is a unique microfluidics instrument designed to enhance key immunotherapy potency assays, including cell-killing and cytokine secretion assays. By encapsulating living cells in highly stable double-emulsion droplets, Xdrop creates individual microenvironments that enable high-throughput, sensitive, and accurate functional analysis with single-cell resolution. What sets Xdrop apart is the ability to analyze and sort its droplets using flow cytometers and sorters. This feature makes it an ideal platform for cell function assays, allowing researchers to expand their studies to include not only surface-target interactions but also secreted targets and complex cell-cell interactions. Xdrop changes how you analyze cells! Learn more about our members here: https://shorturl.at/2AkEI

How should Sweden take the lead in global ATMP - and how should the vision continue to evolve? ATMP2030 has unveiled its Future Vision for Advanced Therapy Medicinal Products (ATMP), aiming to become a global leader by 2030/2035. This vision focuses on building a strong national infrastructure to enable faster clinical trials, enhanced funding, and seamless collaboration between academia, industry and healthcare. Ker priorities include: 💡Competence development - Ensuring future-ready expertise  🤝International Collaboration - Strengthening Sweden’s global role ⚡World-Class Clinical Trials - Accelerating patient access and research 💰Sustainable Funding - Establishing innovative financing models ”By working as one unified ecosystem, Sweden can become a hub for ATMP in Europe,” says the ATMP2030 core team. With the initiative entering a new phase, the ATMP Association and Coordination Function for ATMP in Sweden will be key drivers in sustaining progress.

And now we bid farewell to Heather Main as Project Manager of ATMP Sweden! Heather began in building the platform in 2018 and has worked since then with the Swedish ATMP network to pull together what is now the internationally recognised ATMP Sweden platform. Henrik Simonsson now officially takes the reigns from Heather in what will be an exciting new phase of development for the platforms 🤩 "It has been such an honour and pleasure to work with the Swedish ATMP network to, not only begin to understand myself what an ATMP is and the essential needs for broad stakeholder engagement, but to build this internationally recognised platform that is truly one of a kind in the dedication to engage the stakeholder breadth," says Heather. "This type of network is essential for bench to standard of care development, as opposed to 'bench to bedside', through knowledge sharing, awareness, collaboration and most importantly respect. I look forward to this exciting new phase with my own consulting company HOYA and to support Henrik in his goals for developing the ATMP Sweden platforms further". As a quick note, please do not email Heather's @regionstockholm email for ATMP Sweden related issues, but email Henrik at info@atmpsweden.se. For issues specific to Heather but not to ATMP Sweden, please email heather@hoyaconsulting.se

Welcome Saveen & Werner to ATMP Sweden membership! "Saveen & Werner is represented in Sweden, Norway, Denmark and Finland with its own subsidiaries to provide service to customers in all four markets. The goal is to be a "one stop shop" and provide customers with a wide selection of high-quality products from leading global suppliers. Availability, reliability and quality are important parts of the company's value base. Big enough to be able. Small enough to care." Read more about our members here: https://shorturl.at/ykK7t

Welcome Anthony Nolan to ATMP Sweden membership! "Anthony Nolan created the Cell Therapy & Laboratory Services team to provide researchers & the industry with the most comprehensive end-to-end solutions in cellular starting materials. Today, we are a seamless organisation that combines world-renowned research, donor capabilities and clinical expertise to make possible real advances in cell & gene therapy development and commercialisation. Along with our vast donor registry of over 900,000 donors and 50 years of experience we offer a range of products from healthy adult donors as well as laboratory services for to process and isolate key cells from these materials. We also work with several of our clients to provide HLA typing services and specific cryopreservation protocols based on our their needs." Read more about our members here: https://shorturl.at/ykK7t